drugset / Trial / NCT03537404
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
RandomizedCrossoverOpen-labelTreatment
Summary
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction, safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and Tenofovir disoproxil fumarate (part 1) and Narlaprevir, Ritonavir and Raltegravir (part 2) are administered in combination to healthy volunteers.
Timeline
- Start
- 2017-04-24
- Primary completion
- 2017-06-24
- Completion
- 2017-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Narlaprevir | Small molecule | 200 mg | Oral |
| Subject | Raltegravir | Other / unclassified | 400 mg | Oral |
| Subject | Tenofovir disoproxil fumarate | Small molecule | 300 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |
Indications
No indication recorded.